Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , , , , |
---|---|
Formaat: | Artikel |
Taal: | Engels |
Gepubliceerd in: |
Philipps-Universität Marburg
2023
|
Onderwerpen: | |
Online toegang: | PDF Full text |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
No abstracts were found for this record.